2026-04-19T15:54:27Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2043232025-12-05T12:43:58Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Lejeune, Marylène author Reverté, Laia author Gallardo, Noèlia author Sauras, Esther author Bosch, Ramon author Mata, Daniel author Roso Llorach, Albert author Petit, Anna author Peg, Vicente author Riu, Francisco author García Fontgivell, Joan author Relea, Fernanda author Vieites, Begoña author Cruz Merino, Luis de la author Arenas Prat, Meritxell author Rodriguez, Valeri author Galera, Juana author Korzynska, Anna author Plancoulaine, Benoît author Álvaro, Tomás author López, Carlos author 2023-12-11T09:57:15Z 2023-12-11T09:57:15Z 2023-07-11 2023-08-17T11:46:03Z Triple-negative breast cancer (TNBC) is particularly challenging due to the weak or absent response to therapeutics and its poor prognosis. The effectiveness of neoadjuvant chemotherapy (NAC) response is strongly influenced by changes in elements of the tumor microenvironment (TME). This work aimed to characterize the residual TME composition in 96 TNBC patients using immunohistochemistry and in situ hybridization techniques and evaluate its prognostic implications for partial responders vs. non-responders. Compared with non-responders, partial responders containing higher levels of CD83+ mature dendritic cells, FOXP3+ regulatory T cells, and IL-15 expression but lower CD138+ cell concentration exhibited better OS and RFS. However, along with tumor diameter and positive nodal status at diagnosis, matrix metalloproteinase-9 (MMP-9) expression in the residual TME was identified as an independent factor associated with the impaired response to NAC. This study yields new insights into the key components of the residual tumor bed, such as MMP-9, which is strictly associated with the lack of a pathological response to NAC. This knowledge might help early identification of TNBC patients less likely to respond to NAC and allow the establishment of new therapeutic targets. Adjuvants immunològics Càncer de mama Immunological adjuvants Breast cancer Matrix Metalloproteinase-9 Expression Is Associated with the Absence of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients